Castuner

RhAPPcast

Rheumatology Advanced Practice Providers (RhAPP)

This is the official podcast of Rheumatology Advanced Practice Providers (RhAPP), a non-profit 501c3 organization dedicated to developing educational programs, providing professional advancement services, and assembling resources for—and guided by—advanced practice providers (APPs).

Through our peer-to-peer network, we seek to support the integral role APPs play in the rheumatology healthcare community by providing the most relevant and timely information and communication for the treatment of their patients with rheumatic diseases.

Сайт подкаста

Слушайте в своём приложении

Эпизоды

230 эпизодов

  1. RhAPPcast: A Case-Based Approach to Early Intervention and Renal Preservation in Lupus Nephritis 20:58
  2. RhAPPcast: Introducing the RhAPP Advocacy Program 9:57
  3. FAQ: How Does Combination Therapy of Guselkumab and Golimumab Work in PsA? 1:37
  4. FAQ: How Does Guselkumab Affect Pregnancy Outcomes? 7:03
  5. Journal Club: Guselkumab + Golimumab in Active PsA: Week 24 Phase 2a Results 3:45
  6. Medication Review: Belimumab Dosing Strategies and Administration in SLE and Lupus Nephritis 5:17
  7. FAQ: What is the difference between BASDAI and ASDAS? 4:44
  8. Medication Review: Guselkumab Label Updates Secondary to Data From the APEX and SOLSTICE Studies 4:32
  9. RhAPPcast: The Steroid Tightrope: Managing GC Toxicity in PMR 29:38
  10. FAQ: What is the MOA of guselkumab and icotrokinra? 1:36
  11. FAQ: How Should Treatment Duration be Approached After Remission or Low Disease Activity in SLE? 2:49
  12. RhAPPcast: SLEDAI Training: Disease Activity in Lupus and Organ Damage Recognition 2:23
  13. Medication Review: SLE & Lupus Nephritis: Biologic MOAs Explained 2:23
  14. FAQ: Why is Earlier Intervention Important in Lupus? 2:24
  15. Journal Club: Deep Dive Into Radiographic Progression/Data in PsA From The PsA-1 Manuscript 9:00
  16. FAQ: How Does Early Intervention and Steroid Reduction Impact Long Term Organ Damage in Lupus 2:24
  17. Journal Club: Efficacy & Safety of Nanoencapsulated Sirolimus Plus Pegadricase 7:31
  18. FAQ: What Is the Total Improvement Score and How Should It Be Interpreted in IIM Clinical Trials? 1:32
  19. FAQ: What Is the Role of Autoantibodies in Disease Progression and Treatment Response in IIM? 2:09
  20. RhAPPcast: The True Cost of Gout: Work, Wellness, and Daily Life 25:14
  21. FAQ: What Are Key Diagnostic Considerations and Limitations of Antibody Testing in IIM? 1:06
  22. Journal Club Review: Deucravacitinib in Active PsA: 52-Week Efficacy and Safety From POETYK PsA-2 7:58
  23. RhAPPcast: Cracking the Code: A Rheum Derm Neuro Multispecialty Case Approach to Myositis 34:07
  24. RhAPPcast: Beyond the Joint: Uncontrolled Gout as a Systemic Disease 25:50
  25. Journal Club Review: TOGETHER-PsA Trial 6:42
  26. FAQ: How Do Clinical Manifestations and Histopathologic Features Vary Across Myositis Subtypes? 9:01
  27. FAQ: What Are the Key Unmet Needs in the Treatment of Idiopathic Inflammatory Myopathies? 5:00
  28. RhAPPcast: Switch, Don’t Cycle: Interpreting the SELECT-SWITCH Trial and What It Means for RA Care 24:34
  29. RhAPPcast: Treat-to-Target in SLE: DORIS Remission Real in Practice 35:35
  30. RhAPPcast: Pharmacists in Rheumatology 31:43
  31. RhAPPcast: EULAR Osteoporosis RhAPP Up: Part 3 17:59
  32. RhAPPcast: EULAR Osteoporosis RhAPP Up: Part 2 21:13
  33. RhAPPcast: EULAR Osteoporosis RhAPP Up: Part 1 23:16
  34. RhAPPcast: EULAR PsA RhAPP Up: Part 3 14:35
  35. RhAPPcast: EULAR PsA RhAPP Up: Part 2 13:09
  36. RhAPPcast: EULAR PsA RhAPP UP: Part 1 16:39
  37. RhAPPcast: EULAR ILD RhAPP Up: Part 3 20:11
  38. RhAPPcast: EULAR ILD RhAPP Up: Part 2 14:23
  39. RhAPPcast: EULAR ILD RhAPP UP: Part 1 19:51
  40. RhAPPcast: TYK2 Inhibition in PsA, Sjögren’s and SLE: What APPs Need to Know as Future Uses Emerge 19:43
  41. Journal Club Review: SURMOUNT-5 4:14
  42. Medication Review: Deucravacitinib Dosing, Administration, DDIs, & Safety in Clinical Practice 2:08
  43. Podcast: Weight, Wellness, and PsA: Empowering Conversations & Action in the Rheumatology Clinic 18:16
  44. FAQ: TYK2/STAT Signaling: The Immunologic Rationale for TYK2 Therapy in SLE & Sjögren’s Disease 10:55
  45. RhAPPcast: From Prescription to Possession: Understanding Medicare Access & Cap and Smooth 23:42
  46. FAQ: What Is Minimal Disease Activity in PsA and How Does Deucravacitinib Perform at 52 Weeks? 4:46
  47. FAQ: What Guideline Recommendations Exist Pertaining to Managing obesity in Patients With PsA? 3:10
  48. RhAPPcast: Identification and Diagnosis of XLH: A Story of Family History 25:45
  49. Medication Review: What Is the Safety Profile of Tirzepatide? 3:22
  50. Medication Review: Tirzepatide Starting Dose & Titration for Optimal Outcomes 3:16